Augustine Therapeutics’ Post

The Life Science sector continues to thrive with groundbreaking developments and major investments. Here are some of the most notable highlights from this week: Rezolute, Inc. has received FDA clearance of its IND application for a Phase 3 registrational study of RZ358, targeting the treatment of hypoglycemia due to tumor hyperinsulinism. Exelixis announced that the U.S. FDA has accepted its supplemental new drug application for Cabozantinib, aimed at patients with advanced neuroendocrine tumors. Shinobi Therapeutics secured a $59 million grant from the Japanese Agency for Medical Research and Development. Sangamo Therapeutics, Inc. signed a licensing agreement with Genentech, which could be worth up to $1.9 billion. Karius obtained a BARDA contract to expand the agnostic detection of pathogens. Plonts launched its plant-based cheese with a $12 million seed round in New York City and San Francisco. Invenio Imaging enrolled the first patients in a U.S. pivotal study of its AI-based image analysis module for lung cancer. Stay tuned for more updates as we continue to follow the latest trends and breakthroughs in the life sciences industry! #LifeScience #Biotech #HealthTech #Innovation #AI #Healthcare #ClinicalTrials #FDAApproval #Pharma #LifeScience #HealthcareInnovation #AIinHealthcare #Biopharma #DrugDevelopment #Pharmaceuticals #BiotechNews #MedTech #ResearchAndDevelopment #FDA

Meet Claudio Dagostin at the 9th RSC-BMCS Fragment-based Drug Discovery Meeting. Discover our expertise in Fragment based drug discovery. The event promises a dynamic lineup of presentations, including topics like leveraging fragment-based drug discovery (FBDD) to inform other screening platforms, the application of automated synthesis to off-DNA PAC-FragmentDEL hits and crude reaction screens for rapid fragment elaboration, and exploring new oncology targets from fragment leads. As an integrated drug discovery service provider, we're thrilled to be part of this event. We strive to stay at the forefront of advancements in 𝐟𝐫𝐚𝐠𝐦𝐞𝐧𝐭 𝐛𝐚𝐬𝐞𝐝 𝐝𝐫𝐮𝐠 𝐝𝐢𝐬𝐜𝐨𝐯𝐞𝐫𝐲 research so that we can fully support our pharma and biotech collaborators to progress their novel drug targets which will ultimately benefit human health. To schedule a meeting, reach out to us at discovery@o2h.com. Let's connect and explore possibilities! #Fragments24 #fbdd #fragments #PrecisionMedicine #TherapeuticDevelopment #drugdiscovery #InnovativeScience #SeedingNewIdeas

🚨 LAST CHANCE ALERT! Today is your last chance to save up to $450 on your pass for the 3𝒓𝒅 𝑮𝑷𝑪𝑹𝒔-𝑻𝒂𝒓𝒈𝒆𝒕𝒆𝒅 𝑫𝒓𝒖𝒈 𝑫𝒊𝒔𝒄𝒐𝒗𝒆𝒓𝒚 𝑺𝒖𝒎𝒎𝒊𝒕 (March 5 – 7, Boston, MA)!🚨   Secure your seat here - https://ter.li/0c5udn   Bringing two brand new jam-packed tracks of content (Target ID & Validation and Hit ID & Optimization), don’t miss out on your ultimate chance to unite with 100+ GPCR experts devoted to accelerating the discovery of new, transformative small molecules and biologics. This industry dedicated meeting is your one-stop-shop to network and gain the latest insight with industry experts from Superluminal Medicines Inc., Confo Therapeutics, InterAx Biotech, , Novartis, Sosei Heptares, Abilita Therapeutics, Inc., Eli Lilly and Company, DJS Antibodies, Genentech, Northwestern University, AstraZeneca, Tectonic Therapeutic, Inc., Amgen, Domain Therapeutics, PrecisionLife, Generate:Biomedicines, University of Glasgow, Cumulus Oncology, Gilgamesh Pharmaceuticals and many more.   👩🔬 Want to showcase your own work in the discussion?👨🔬 Included in your ticket is the opportunity to demonstrate your own innovations at our dedicated poster session, find out more here: https://ter.li/0c5udn   #GPCR #drugdiscovery #SBDD #smallmolecules #biologics #membraneprotein

Rosa is excited to be presenting results from a number of collaborations at #ACoP15 in a couple of weeks. Monday, November 11th A translational QSP model to characterize the preclinical pharmacodynamics of combining a KRAS G12C inhibitor with a SHP2 inhibitor (M-068) in collaboration with Genentech. Wednesday, November 13th Adaptation of a Published Kidney Disease QSP Model to Represent Autosomal-Dominant Polycystic Kidney Disease and Evaluate Treatment Options (W-033) in collaboration with Otsuka Pharmaceutical Co., Ltd. Parallel Tempering for Generation of Virtual Patients and Virtual Populations (W-034) Mathematical optimization of a thrombopoiesis quantitative systems pharmacology (QSP) model (W-102) #QSP #MIDD #drugdevelopment

One of the Keynote Speakers is Director, Office of New Drugs, CDER, FDA. I can’t wait to hear what he has to say about the acceptance of QSP and MIDD. Of course, #ACoP15 will be a great opportunity to connect with partners and the community. If you are attending and want to schedule time for a conversation, add time on my calendar. https://lnkd.in/e_49E_Tt We can discuss how you are combining AI/ML with QSP, the headwinds in promoting QSP in your organization, or your costume for the Crystal Ball social event. #quantitativepharmacology #modelinformeddrugdevelopment #FDA

Glad to share the recent publication borne of a long-term and fruitful collaboration between Sheffield Hallam University and AstraZeneca. Here, we exemplify how the integration of advanced spatial omics (#metabolomics and #proteomics) technologies as #MSI (IMSIS home of MSI | IMS), #IMC and #MALDI-IHC (AmberGen) can support the use of 3D cell cultures in the context of #3Rs aligned pharmaceutical development to inform about efficacy and for a better translation to clinic. Special thanks to Sophie Pearce and all co-authors Dr Laura M Cole PhD Clench Malcolm R. Neil Cross David Smith Lucy Flint Emmanuelle Claude James Langridge Richard Goodwin. More to come at the American Society For Mass Spectrometry (ASMS) #ASMS2024 next week with additional exciting data! Link to the paper: https://lnkd.in/dRW2bfWV #WhatScienceCanDo #massspectrometry #omics #proteomics #metabolomics #spatialbiology #pharmaceuticals #molecularimaging #cancerresearch #drugdioscovery #organoids #oncology

Database of Publicly Announced U.S. FDA RMAT Designations (104 Total) - https://lnkd.in/e6pEsZH To date, what number of U.S. FDA-approved RMATs have been issued and to whom have they been awarded? The answer is that 104 RMAT (Regenerative Medicine Advanced Therapy) designations have been publicly announced by biotech and pharma companies. However, the FDA states it has received 279 requests and issued 128, which means that a handful are not yet public knowledge. Therefore, a few companies are operating in stealth mode with regard to their RMAT designations and approximately 46% of RMAT applications get approved (128 approvals / 279 applications = 45.9%). Thus far, Rocket Pharmaceuticals is the only company to receive four RMATs, while three other companies (AlloVir, CRISPR Therapeutics, and Humacyte) have received three RMATs to date. Additionally, 10 companies (Abeona Therapeutics, Adaptimmune, Allogene Therapeutics, Athersys, CARsgen Therapeutics, Cook MyoSite, Mesoblast Limited, Ocugen, Orchard Therapeutics - U.S., and Sangamo Therapeutics, Inc. Therapeutics) have managed to secure two RMAT designations from the U.S. FDA. Learn more or claim the database here: https://lnkd.in/e6pEsZH #celltherapy #genetherapy #tissueengineering #rmat

Biotechnology Weekly Update - February 01, 2024 🔷 CAR-T Therapies Linked To Secondary Cancer Risk?  The FDA has mandated black box warning for Abecma, Breyanzi, Carvykti, Kymriah, Tecartus and Yescarta to highlight T-cell malignancy risk in their labels. https://lnkd.in/g-zPBKWh 🔷 Dyne Shares Surge To 2-Year High  Several pharmaceutical firms have expressed interest in a potential acquisition of clinical-stage muscle disease company Dyne Therapeutics, as per Bloomberg reports. https://lnkd.in/gARvjkWT 🔷 2024 To Be A Year Of Significant Catalysts For Beam Therapeutics  Beam is set to unveil data from its Phase 1/2 trial of BEAM-101 in Sickle Cell Disease in H2, 2024. JPMorgan has raised the target price on the stock to $40 from $38. https://lnkd.in/gBunkaAU 🔷 Vera Therapeutics Skyrockets Over 120% in a Week Vera stock has been gaining momentum following robust 72-week data from a phase IIb trial of Atacicept in immunoglobulin A nephropathy, reported last week.   https://lnkd.in/gRyZ38E9 🔷 First Recipient of Neuralink’s brain implant In PRIME Study Recovering Well, Says Musk The study is evaluating a brain-computer interface implant in enabling individuals with paralysis to control external devices such as computers. https://lnkd.in/guB3i-j5 Subscribe to RTT Biotech Investor to get timely updates on Biotech & Pharma industry, and access all the timely news, time-sensitive information, and alerts that can enable you to make sound investment decisions. https://bit.ly/3G5cWiS Follow us on  Instagram - https://lnkd.in/d-iJrNib  Twitter- https://lnkd.in/dQ2MykDF Facebook- https://lnkd.in/dzx_W4f3 YouTube - https://lnkd.in/dtqZKd4a #biotech #biotechnology #rttnews #FDA #weeklyupdates #weeklynews #fdaapproved #fdaapproval

Pharma and biotech’s top R&D spenders in 2023: a $153B total with M&A as a focus https://lnkd.in/g_jeNgSf At a time when biotech is still counting its losses as a thaw gradually sets in after the long market winter, pharma has been on a tear. M&A took off in Q4 as the industry’s biggest R&D spenders either rolled the dice on the back of their blockbuster bonanzas, were forced to address gaping holes in the pipeline in the face of looming patent expirations, or simply had no choice in the face of repeated setbacks. Bioregnum Opinion Column by John Carroll For some, it was all of the above. As a result, Merck flipped into the lead position generally occupied by Roche with an M&A-inflated expense line for research. The companies joined a hunt for new drugs frequently focused on Phase III; premiums are in — heavy preclinical risks are out of favor. The majors followed some well-worn paths into immunology and oncology…. Click here to view original post Click Here to Publish/Feature Your Company or Product News with Biotech Networks

Streamline Preclinical Drug Discovery: PBMC-Humanised Mouse Models Discover a clinically predictive and reproducible platform developed by The Jackson Laboratory for simultaneous efficacy and safety assessment. This platform identifies patient-therapy combinations at risk of developing severe inflammatory syndrome, a potentially fatal complication. Optimise the safety profiles of your immunomodulatory therapeutics before first-in-human trials by leveraging this platform. In this bispecific case study, learn how the platform: - Captured donor-specific responses and their impact on efficacy and safety profiles - Identified potential toxicity risks  - Correlated cytokine release and tumour growth inhibition in the context of bispecifics - Seize this opportunity to gain valuable insights into the future of efficient preclinical drug discovery and development. Download Case Study https://lnkd.in/eQqpE6v8 Brought to you by The Jackson Laboratory #DrugDiscovery #DrugDevelopment #TCells Jackson Laboratories